A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

← catalyst calendar

NCT06733935 · readout ≤ 804 d

Sponsored by Nkarta, Inc. (industry) · NKTX — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

240estimated

Sites

Countries

Australia, Puerto Rico, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-11-04

actual

When the study began enrolling

Primary completion

Oct 2028

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Oct 2028

estimated

The whole study's end, after follow-up

First posted

2024-12-13

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-07

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Systemic Sclerosis
Idiopathic Inflammatory Myopathies
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Rheumatoid Arthritis

Interventions

Drug: NKX019
Drug: Fludarabine
Drug: Cyclophosphamide

Primary outcomes

what the primary-completion date above is the date OF

Incidence of Dose-limiting toxicities (DLTs) [Safety and Tolerability]

measured The first 28 days after the first NKX019 dose

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

measured From the first administration of NKX019 until the last administration of any study treatment + 30 days

Permalink · NKTX's whole pipeline · Catalyst calendar · Every registered study · What changed